{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:04:13Z","timestamp":1793678653665,"version":"4.5.1"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a relapsing-remitting course and, even with the availability of effective maintenance therapies such as rituximab, relapse rates remain high. Relapse is associated with the accrual of organ damage stemming from both the underlying disease and from the effects of AAV treatments; thus, early detection and proactive prevention are crucial. AAV study populations typically include mixed cohorts of patients with new-onset and relapsing disease. Although data specifically addressing re-induction of remission after relapse are limited, available evidence suggests high remission rates when rituximab is combined with glucocorticoids. However, the balance between effective disease control and the potential treatment-related side effects must be carefully considered, and new therapeutic options may help improve this tradeoff. The aim of this review is to explore what is known about relapse risk and relapse management while considering emerging pathogenic and therapeutic paradigms.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1655326","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:40:06Z","timestamp":1758192006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Antineutrophil cytoplasmic antibody-associated vasculitis: insights into relapse risk and future management directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Federico","family":"Alberici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Flossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Loudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladdin J.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01166","article-title":"Central nervous system involvement in ANCA-associated vasculitis: what neurologists need to know","volume":"9","author":"Zheng","year":"2018","journal-title":"Front Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00025-0","article-title":"Myeloperoxidase-specific antineutrophil cytoplasmic antibody-associated vasculitis","volume":"6","author":"Arnold","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00035-3","article-title":"Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis","volume":"6","author":"Falde","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02500317","article-title":"ANCA glomerulonephritis and vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092573","article-title":"Systematic review and metaanalysis of worldwide incidence and prevalence of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis","volume":"11","author":"Redondo-Rodriguez","year":"2022","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.39614","article-title":"Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease","volume":"68","author":"Rhee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e000435","DOI":"10.1136\/rmdopen-2017-000435","article-title":"Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis","volume":"3","author":"Heijl","year":"2017","journal-title":"RMD Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac320","article-title":"Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis","volume":"38","author":"Sanchez Alamo","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002949","article-title":"Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study","volume":"9","author":"Rathmann","year":"2023","journal-title":"RMD Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409129","article-title":"Treatment goals in ANCA-associated vasculitis: defining success in a new era","volume":"15","author":"Alberici","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"69","author":"Merkel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225587","article-title":"Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis","volume":"83","author":"Thiel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.125","article-title":"The complement system as a potential therapeutic target in rheumatic disease","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02790313","article-title":"Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.41011","article-title":"Measuring circulating complement activation products in myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Wu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","article-title":"The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.42410","article-title":"Low concentrations of C5a complement receptor antibodies are linked to disease activity and relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"75","author":"Klapa","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"m1070","DOI":"10.1136\/bmj.m1070","article-title":"ANCA associated vasculitis","volume":"369","author":"Hunter","year":"2020","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"103018","DOI":"10.1016\/j.autrev.2021.103018","article-title":"Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis","volume":"21","author":"Padoan","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez617","article-title":"Comorbidities in ANCA-associated vasculitis","volume":"59","author":"Kronbichler","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"102708","DOI":"10.1016\/j.autrev.2020.102708","article-title":"Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis","volume":"20","author":"Mercuzot","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.39104","article-title":"Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"102302","DOI":"10.1016\/j.jaut.2019.07.001","article-title":"The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"105","author":"Berti","year":"2019","journal-title":"J Autoimmun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222479","article-title":"Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission","volume":"82","author":"Gamerith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.009","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key288","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70001","article-title":"Safety of avacopan for the treatment of ANCA-associated vasculitis: combined data from three clinical trials","volume":"7","author":"Merkel","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173773","article-title":"Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives","volume":"10","author":"Treppo","year":"2021","journal-title":"J Clin Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez640","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.jaci.2016.08.051","article-title":"Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"139","author":"Alberici","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/art.42556","article-title":"Association between plasma rituximab concentration and the risk of major relapse in antineutrophil cytoplasmic antibody-associated vasculitides during rituximab maintenance therapy","volume":"75","author":"Khoudour","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13417","article-title":"Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study","volume":"291","author":"Thietart","year":"2022","journal-title":"J Intern Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/art.39620","article-title":"HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: A cohort study","volume":"68","author":"Hilhorst","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.166107","article-title":"PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease","volume":"8","author":"Chen","year":"2023","journal-title":"JCI Insight"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","article-title":"Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement","volume":"18","author":"Casal Moura","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad197","article-title":"Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function","volume":"39","author":"Mescia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222439","article-title":"The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study","volume":"81","author":"McDermott","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14728","article-title":"Anti-neutrophil cytoplasmic antibody monitoring in vasculitis patients to predict relapse","volume":"26","author":"Schuster","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B69","doi-asserted-by":"publisher","first-page":"152189","DOI":"10.1016\/j.semarthrit.2023.152189","article-title":"Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy-A meta-analysis","volume":"60","author":"Pope","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex001","article-title":"Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate","volume":"56","author":"Salmela","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05100-9","article-title":"Overview of infections as an etiologic factor and complication in patients with vasculitides","volume":"42","author":"Theofilis","year":"2022","journal-title":"Rheumatol Int"},{"key":"B72","article-title":"Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study","author":"Padoan","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac716","article-title":"Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study","volume":"62","author":"Podesta","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"103130","DOI":"10.1016\/j.jaut.2023.103130","article-title":"Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: A cohort study","volume":"142","author":"Liberatore","year":"2024","journal-title":"J Autoimmun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejim.2023.06.021","article-title":"Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"117","author":"Benavides-Villanueva","year":"2023","journal-title":"Eur J Intern Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1136\/annrheumdis-2021-220496","article-title":"Correspondence on \u2018Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort\u2019","volume":"80","author":"Salviani","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224489","article-title":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial","volume":"83","author":"Zonozi","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04752-9","article-title":"Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis","volume":"41","author":"Speer","year":"2021","journal-title":"Rheumatol Int"},{"key":"B81","article-title":"A multicenter, randomized, controlled trial to evaluate the effects of low-dose glucocorticoids compared to stopping glucocorticoids to maintain remission of granulomatosis with polyangiitis: the TAPIR trial","volume":"76","author":"Merkel","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/art.42843","article-title":"Risk of relapse of antineutrophil cytoplasmic antibody-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids","volume":"76","author":"Junek","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B83","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B85","doi-asserted-by":"publisher","first-page":"6369814","DOI":"10.1155\/2018\/6369814","article-title":"Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: A clinical long-term follow-up study","volume":"2018","author":"Salmela","year":"2018","journal-title":"Int J Nephrol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez016","article-title":"Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification","volume":"58","author":"Deshayes","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4019-0","article-title":"Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes","volume":"37","author":"Felicetti","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae409","article-title":"Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study","volume":"64","author":"Gialouri","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e061339","DOI":"10.1136\/bmjopen-2022-061339","article-title":"ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial","volume":"12","author":"Dirikgil","year":"2022","journal-title":"BMJ Open"},{"key":"B90","doi-asserted-by":"publisher","first-page":"102514","DOI":"10.1016\/j.autrev.2020.102514","article-title":"Usefulness of vasculitis biomarkers in the era of the personalized medicine","volume":"19","author":"Csernok","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B91","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","article-title":"Relapse in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis","volume":"5","author":"Salama","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00187-5","article-title":"Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort","volume":"6","author":"Gisslander","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"102759","DOI":"10.1016\/j.autrev.2021.102759","article-title":"The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies","volume":"20","author":"Ramponi","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803175","article-title":"A personalized rituximab retreatment approach based on clinical and B-cell biomarkers in ANCA-associated vasculitis","volume":"12","author":"Arnold","year":"2021","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"8209737","DOI":"10.1155\/2020\/8209737","article-title":"Increased frequencies of switched memory B cells and plasmablasts in peripheral blood from patients with ANCA-associated vasculitis","volume":"2020","author":"Elmer","year":"2020","journal-title":"J Immunol Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/art.42388","article-title":"Autoreactive plasmablasts after B cell depletion with rituximab and relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"75","author":"Berti","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/art.39814","article-title":"Association of serum calprotectin (S100A8\/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Pepper","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003477","article-title":"Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial","volume":"9","author":"Romand","year":"2023","journal-title":"RMD Open"},{"key":"B99","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/ckj\/sfac257","article-title":"Combining neutrophil and macrophage biomarkers to detect active disease in ANCA vasculitis: a combinatory model of calprotectin and urine CD163","volume":"16","author":"Anton-Pampols","year":"2023","journal-title":"Clin Kidney J"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key260","article-title":"Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome","volume":"58","author":"Wester Trejo","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1038\/s41467-025-58550-7","article-title":"Neutrophil single-cell analysis identifies a type II interferon-related subset for predicting relapse of autoimmune small vessel vasculitis","volume":"16","author":"Nishide","year":"2025","journal-title":"Nat Commun"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021030382","article-title":"The clinical application of urine soluble CD163 in ANCA-associated vasculitis","volume":"32","author":"Moran","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh487","article-title":"Urinary monocyte chemoattractant protein-1 (MCP - 1) is a marker of active renal vasculitis","volume":"19","author":"Tam","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000311","article-title":"Urinary CD4 + T cells predict renal relapse in ANCA-associated vasculitis","volume":"35","author":"Prskalo","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae018","article-title":"Long-term outcome of kidney function in patients with ANCA-associated vasculitis","volume":"39","author":"Sachez-Alamo","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00092-9","article-title":"The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Strand","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-024-00929-4","article-title":"Effective management of necrotizing crescentic glomerulonephritis using an aggressive combination therapy including avacopan in a patient double-seropositive for anti-GBM antibodies and ANCA: a case report","volume":"14","author":"Tanaka","year":"2024","journal-title":"CEN Case Rep"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2020-eular.1073","article-title":"A Randomized, double-blind, active-controlled study of avacopan in anti-neutrophil cytoplasmic antibody (ANCA-) associated vasculitis","volume":"79","author":"Merkel.","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.1065","article-title":"Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: A steroid-sparing option","volume":"7","author":"Gabilan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae359","article-title":"Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicenter real-world study","volume":"64","author":"Gabilan","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1136\/annrheumdis-2023-eular.4738","article-title":"Avacopan in the real-life practice: Evaluation of efficacy, safety, and impact on quality of life in the early stages of treat,ment","volume":"82","author":"Treppo","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad090","article-title":"Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines\/recommendations","volume":"38","author":"Casal Moura","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.2215\/\/CJN.10550620","article-title":"PEXIVAS: the end of plasmapheresis for ANCA-associated vasculitis","volume":"16","author":"De Vriese","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20649","article-title":"Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"64","author":"Tomasson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ard.2025.06.851","article-title":"Care gaps in ANCA-associated vasculitis (AAV): Exploring unmet needs and misalignments between patients and physicians","volume":"84","author":"Padoan","year":"2025","journal-title":"Ann Rheumatic Dis"},{"key":"B123","doi-asserted-by":"publisher","first-page":"100595","DOI":"10.1016\/j.xkme.2022.100595","article-title":"Plasma exchange for ANCA-associated vasculitis: an international survey of patient preferences","volume":"5","author":"Collister","year":"2023","journal-title":"Kidney Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13063-023-07218-y","article-title":"A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol","volume":"24","author":"McClure","year":"2023","journal-title":"Trials"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae286","article-title":"Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus","volume":"63","author":"Arends","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B127","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.1038\/s41467-024-52525-w","article-title":"Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis","volume":"15","author":"Engesser","year":"2024","journal-title":"Nat Commun"},{"key":"B128","first-page":"Abstract 0823","article-title":"A Randomized, double-blind, placebo-controlled trial of Abatacept for the treatment of relapsing, non-severe granulomatosis with polyangiitis","volume":"76","author":"Langford","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa818","article-title":"Immune checkpoint inhibitor-induced granulomatosis with polyangiitis","volume":"60","author":"Hung","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e083277","DOI":"10.1136\/bmjopen-2023-083277","article-title":"Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas","volume":"14","author":"McGovern","year":"2024","journal-title":"BMJ Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655326\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:40:09Z","timestamp":1758192009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655326\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":131,"alternative-id":["10.3389\/fimmu.2025.1655326"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1655326","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1655326"}}